New United States patent granted for Nventa's Coval HPV fusions to treat patients with HPV-related diseases.
Publication Date: 01-SEP-07
Publication Title: BIOTECH Patent News
Format: Online

Read this article now
Try Goliath Business News - FREE!
You can view this article PLUS...

  • Over 5 million business articles
  • Hundreds of the most trusted magazines, newswires, and journals (see list)
  • Premium business information that is timely and relevant
  • Unlimited Access

Now for a Limited Time, try Goliath Business News
Free for 7 Days!

Tell Me More   Terms and Conditions

Purchase this article for $4.95

Description

Nventa Biopharmaceuticals Corporation (San Diego, CA) announced that the United States Patent and Trademark Office has issued Patent Number 7,262,014 to Nventa covering compositions and methods for inducing or enhancing immune responses to a human papillomavirus (HPV) antigen with or without the use of an adjuvant. The company's CoVal...



More articles from BIOTECH Patent News
University of Southern California obtains United States patent., September 01, 2007
Celtrix obtains United States patent., September 01, 2007
Monsanto obtains United States patent., September 01, 2007
ProChon obtains United States patent., September 01, 2007
Degussa obtains United States patent., September 01, 2007

Looking for additional articles?
Click here to search our database of over 3 million articles.